{"id":"trifluridine-and-tipiracil","safety":{"commonSideEffects":[{"rate":"70","effect":"Neutropenia"},{"rate":"65","effect":"Anemia"},{"rate":"50","effect":"Thrombocytopenia"},{"rate":"45","effect":"Nausea"},{"rate":"40","effect":"Fatigue"},{"rate":"35","effect":"Diarrhea"},{"rate":"30","effect":"Vomiting"},{"rate":"25","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL235668","moleculeType":"Small molecule","molecularWeight":"242.67"},"_dailymed":{"setId":"f5beed22-d71d-4c0d-8dca-2c7317d65d85","title":"LONSURF (TRIFLURIDINE AND TIPIRACIL) TABLET, FILM COATED [TAIHO PHARMACEUTICAL CO., LTD.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Trifluridine acts as a thymidylate synthase inhibitor and antimetabolite that incorporates into DNA, causing strand breaks and cell death in rapidly dividing cancer cells. Tipiracil inhibits thymidine phosphorylase, which normally degrades trifluridine, thereby increasing systemic exposure and efficacy of the active drug. This combination allows lower doses of trifluridine to achieve therapeutic effect while reducing toxicity.","oneSentence":"Trifluridine is a nucleoside analog that inhibits thymidylate synthase and gets incorporated into DNA to damage cancer cells, while tipiracil is a thymidine phosphorylase inhibitor that enhances trifluridine bioavailability.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:04.307Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer (previously treated)"},{"name":"Metastatic gastric cancer (previously treated)"}]},"trialDetails":[{"nctId":"NCT07492173","phase":"NA","title":"Bioequivalence Study of Trifluridine and Tipiracil Hydrochloride Tablets on Fasting and Fed in Humans","status":"COMPLETED","sponsor":"Shandong New Time Pharmaceutical Co., LTD","startDate":"2022-11-21","conditions":"Solid Tumor Cancer","enrollment":76},{"nctId":"NCT07491159","phase":"PHASE1, PHASE2","title":"Fruquintinib Plus Checkpoint Inhibitor Combined or Sequential TAS-102 in Colorectal Cancer Patients Who Progressed on Second-line Standard Therapy: a Prospective, Multi-cohort, Single-centered, Phase Ib/II Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-07-01","conditions":"Colorectal Cancer","enrollment":106},{"nctId":"NCT07011550","phase":"PHASE2","title":"Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer","status":"SUSPENDED","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-08-15","conditions":"Microsatellite-stable Colorectal Cancer, Standard of Care, Nivolumab","enrollment":7},{"nctId":"NCT07483684","phase":"PHASE3","title":"A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs","status":"NOT_YET_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2026-03","conditions":"HER2 IHC3+ Advanced Colorectal Cancer","enrollment":142},{"nctId":"NCT05806931","phase":"PHASE2","title":"Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2023-05-17","conditions":"Colon Cancer, Rectal Cancer","enrollment":50},{"nctId":"NCT06992258","phase":"PHASE2","title":"A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Criterium, Inc.","startDate":"2025-10-27","conditions":"Colorectal Cancer","enrollment":120},{"nctId":"NCT06607458","phase":"PHASE2","title":"Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease","status":"RECRUITING","sponsor":"Delcath Systems Inc.","startDate":"2025-08-05","conditions":"Refractory Metastatic Colorectal Cancer","enrollment":90},{"nctId":"NCT03223779","phase":"PHASE1, PHASE2","title":"Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2017-10-13","conditions":"Colorectal Cancer","enrollment":52},{"nctId":"NCT06346392","phase":"PHASE3","title":"AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-03-04","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":572},{"nctId":"NCT05343013","phase":"PHASE2","title":"TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-06-06","conditions":"Colorectal Cancer","enrollment":25},{"nctId":"NCT03686488","phase":"PHASE2","title":"TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2018-12-20","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Gastric Cancer","enrollment":23},{"nctId":"NCT04511039","phase":"PHASE1","title":"Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2021-06-08","conditions":"Advanced Malignant Solid Neoplasm, Clinical Stage III Gastroesophageal Junction Adenocarcinoma, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma","enrollment":45},{"nctId":"NCT06137170","phase":"","title":"A Real-World Study to Learn More About the Order of Different Treatments and Their Effects in People With Metastatic Colorectal Cancer Receiving Their Third and Fourth Line of Treatment","status":"COMPLETED","sponsor":"Bayer","startDate":"2024-03-01","conditions":"Metastatic Colorectal Cancer","enrollment":121},{"nctId":"NCT05083481","phase":"PHASE1, PHASE2","title":"A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2021-10-19","conditions":"Advanced Solid Tumors","enrollment":366},{"nctId":"NCT06356311","phase":"PHASE3","title":"A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-05-03","conditions":"Gastroesophageal Cancer","enrollment":450},{"nctId":"NCT07318389","phase":"EARLY_PHASE1","title":"ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-06-10","conditions":"Dynamic Tumor Resistance, Metastatic Colorectal Cancer","enrollment":100},{"nctId":"NCT07146646","phase":"PHASE2","title":"Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer","status":"RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2025-12-01","conditions":"Biliary Tract Cancer, Biliary Tract Neoplasms, Cholangiocarcinoma","enrollment":27},{"nctId":"NCT05919264","phase":"PHASE1, PHASE2","title":"FOG-001 in Locally Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Parabilis Medicines, Inc.","startDate":"2023-05-23","conditions":"Cancer, Colorectal Cancer, Solid Tumor","enrollment":575},{"nctId":"NCT04109924","phase":"PHASE2","title":"TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2019-12-27","conditions":"Advanced Colorectal Carcinoma, Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma","enrollment":42},{"nctId":"NCT05198934","phase":"PHASE3","title":"Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2022-04-19","conditions":"Colorectal Cancer (CRC)","enrollment":160},{"nctId":"NCT07270991","phase":"PHASE3","title":"Trifluridine/Tipiracil + Fruquintinib Versus Trifluridine/Tipiracil Alone for Metastatic Oeso-gastric Adenocarcinoma","status":"RECRUITING","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2025-12-15","conditions":"Metastatic Oesogastric Adenocarcinoma","enrollment":324},{"nctId":"NCT04776148","phase":"PHASE3","title":"Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-03-29","conditions":"Colorectal Neoplasms","enrollment":563},{"nctId":"NCT05062889","phase":"PHASE2","title":"Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients","status":"SUSPENDED","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2023-05-17","conditions":"Stage II Colon Cancer, Stage III Colon Cancer, HER2-positive Colon Cancer","enrollment":477},{"nctId":"NCT07381764","phase":"PHASE2","title":"ROMANCE: \"Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer\"","status":"NOT_YET_RECRUITING","sponsor":"Gruppo Oncologico Italia Meridionale","startDate":"2026-03-30","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":150},{"nctId":"NCT04626635","phase":"PHASE1, PHASE2","title":"A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-12-21","conditions":"Advanced Solid Tumors","enrollment":933},{"nctId":"NCT07371871","phase":"NA","title":"A Prospective, Single-arm, Exploratory Study of Trifluridine/Tipiracil (TAS-102) Combined With Apatinib as Third-line Therapy for Advanced Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Anhui Provincial Cancer Hospital","startDate":"2026-01-08","conditions":"Advanced Gastric Cancer","enrollment":30},{"nctId":"NCT07361003","phase":"PHASE3","title":"A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2025-11-12","conditions":"Refractory Metastatic Colorectal Cancer","enrollment":464},{"nctId":"NCT07286695","phase":"PHASE2","title":"Fruquintinib Combined With Trifluridine/Tipiracil Versus Bevacizumab Combined With Trifluridine/Tipiracil for Advanced Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-12-31","conditions":"Metastatic Colorectal Cancer (CRC), Colorectal Cancer","enrollment":292},{"nctId":"NCT04457297","phase":"PHASE3","title":"Initial Attack on Latent Metastasis Using TAS-102 for ct DNA Identified Colorectal Cancer Patients After Curative Resection","status":"COMPLETED","sponsor":"National Cancer Center Hospital East","startDate":"2020-07-08","conditions":"Colorectal Neoplasms, Trifluridine and Tipiracil, Circulating Tumor DNA","enrollment":243},{"nctId":"NCT07353268","phase":"PHASE2","title":"Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Cancer: Safety, Tolerability, and Efficacy.","status":"NOT_YET_RECRUITING","sponsor":"Tao Zhang","startDate":"2026-01-21","conditions":"Colorectal Cancer","enrollment":76},{"nctId":"NCT03844620","phase":"PHASE2","title":"Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-01-29","conditions":"Refractory Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8","enrollment":100},{"nctId":"NCT04564898","phase":"PHASE1, PHASE2","title":"Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2022-01-25","conditions":"Colorectal Cancer Metastatic","enrollment":48},{"nctId":"NCT05405595","phase":"PHASE1, PHASE2","title":"ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Adagene Inc","startDate":"2022-06-15","conditions":"Advanced/Metastatic Solid Tumors","enrollment":186},{"nctId":"NCT06680622","phase":"PHASE2","title":"Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2025-03-03","conditions":"Metastatic Gastro-esophageal Adenocarcinoma","enrollment":126},{"nctId":"NCT03869892","phase":"PHASE3","title":"Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut de Recherches Internationales Servier","startDate":"2019-03-21","conditions":"Metastatic Colorectal Cancer","enrollment":856},{"nctId":"NCT07280377","phase":"PHASE1, PHASE2","title":"A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab","status":"RECRUITING","sponsor":"Oncolytics Biotech","startDate":"2021-10-27","conditions":"Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified, Pancreatic Cancer Metastatic","enrollment":122},{"nctId":"NCT06856837","phase":"PHASE2","title":"- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases","status":"RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2025-10-27","conditions":"Metastatic Colorectal Cancer","enrollment":140},{"nctId":"NCT04417699","phase":"PHASE2","title":"SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer","status":"COMPLETED","sponsor":"Providence Health & Services","startDate":"2022-07-05","conditions":"Rectal Cancer","enrollment":13},{"nctId":"NCT06245356","phase":"PHASE2","title":"Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2025-03-21","conditions":"Metastatic Colorectal Cancer, Metastatic Gastroesophageal Adenocarcinoma, DPD Deficiency","enrollment":73},{"nctId":"NCT07261709","phase":"PHASE2","title":"Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority Trial","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-12-01","conditions":"Refractory Metastatic Colorectal Cancer","enrollment":236},{"nctId":"NCT05600309","phase":"PHASE3","title":"A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-06-14","conditions":"Colorectal Cancer","enrollment":94},{"nctId":"NCT05438459","phase":"PHASE1, PHASE2","title":"GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites","status":"RECRUITING","sponsor":"Kyushu University","startDate":"2022-06-08","conditions":"Gastric Cancer, Pancreatic Cancer","enrollment":130},{"nctId":"NCT05839951","phase":"","title":"An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions","status":"COMPLETED","sponsor":"Bayer","startDate":"2023-04-24","conditions":"Metastatic Colorectal Cancer (mCRC)","enrollment":818},{"nctId":"NCT04042714","phase":"PHASE2","title":"TAS-102 in Extrapulmonary Neuroendocrine Carcinoma","status":"TERMINATED","sponsor":"Baylor Research Institute","startDate":"2019-08-15","conditions":"High-grade Extra Pulmonary Neuroendocrine Cancer","enrollment":14},{"nctId":"NCT05029882","phase":"PHASE1","title":"Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2021-10-13","conditions":"Non-Small Cell Lung Cancer, Advanced Solid Tumors, Gastroesophageal Adenocarcinoma","enrollment":520},{"nctId":"NCT04104139","phase":"PHASE1","title":"TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2019-12-11","conditions":"Rectal Adenocarcinoma, Stage IIA Rectal Cancer AJCC v8, Stage IIB Rectal Cancer AJCC v8","enrollment":19},{"nctId":"NCT07212933","phase":"PHASE2","title":"The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled Trial","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-07-01","conditions":"Gastric (Stomach) Cancer, Biological Therapy, Immunotherapy","enrollment":90},{"nctId":"NCT06699836","phase":"PHASE2","title":"A Phase 2 Study of Leronlimab in Combination With TAS-102 + Bevacizumab in Previously Treated Participants With mCRC","status":"RECRUITING","sponsor":"CytoDyn, Inc.","startDate":"2025-06-16","conditions":"Metastatic Colorectal Cancer (mCRC)","enrollment":60},{"nctId":"NCT07196345","phase":"PHASE1, PHASE2","title":"TAS-102 Plus Radiotherapy in Elderly ESCC","status":"NOT_YET_RECRUITING","sponsor":"Qianfoshan Hospital","startDate":"2025-09-25","conditions":"ESCC, TAS 102, Radiotherapy","enrollment":45},{"nctId":"NCT04280536","phase":"PHASE1, PHASE2","title":"Phase II Study of FTD/TPI (Lonsurf) in Metastatic Breast Cancers With or Without Prior Exposure to Fluoropyrimidines (LONBRECA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2019-08-14","conditions":"Breast Cancer","enrollment":86},{"nctId":"NCT04489173","phase":"PHASE2","title":"TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Borstkanker Onderzoek Groep","startDate":"2020-09-25","conditions":"Breast Neoplasm, Chemotherapy Effect","enrollment":52},{"nctId":"NCT05064059","phase":"PHASE3","title":"A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-11-10","conditions":"Colorectal Cancer","enrollment":441},{"nctId":"NCT07171554","phase":"NA","title":"Evaluation of a Diagnostic Test to Identify the Best Drugs for Treatment of Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Oncosyne AS","startDate":"2025-09","conditions":"Metastatic Colorectal Cancer (mCRC)","enrollment":75},{"nctId":"NCT05608044","phase":"PHASE2","title":"A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Agenus Inc.","startDate":"2022-11-30","conditions":"Metastatic Colorectal Cancer","enrollment":234},{"nctId":"NCT06887218","phase":"PHASE2","title":"5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2025-05-08","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":57},{"nctId":"NCT06614192","phase":"PHASE3","title":"A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-11-08","conditions":"Metastatic Colorectal Cancer","enrollment":460},{"nctId":"NCT07142421","phase":"PHASE2","title":"A Study of Trifluridine/Tipiracil Combined With Anlotinib as Second-line Treatment for Recurrent and Metastatic Esophageal Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-08-06","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":35},{"nctId":"NCT06764680","phase":"PHASE2","title":"Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-12-31","conditions":"Colorectal Cancer Metastatic, Chemotherapy, Targeted Therapy","enrollment":57},{"nctId":"NCT06238843","phase":"PHASE3","title":"A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2024-06-30","conditions":"Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":450},{"nctId":"NCT07138885","phase":"PHASE2","title":"A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-Line Therapy for Targeted-Immunotherapy-Resistant Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-08-01","conditions":"Hepatocellular Carcinoma (HCC), Second Line Treatment","enrollment":62},{"nctId":"NCT05927857","phase":"PHASE1, PHASE2","title":"Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .","status":"RECRUITING","sponsor":"National Health Research Institutes, Taiwan","startDate":"2024-04-01","conditions":"Metastatic Gastric Adenocarcinoma, Second Line, Chemotherapy","enrollment":45},{"nctId":"NCT04166604","phase":"PHASE2","title":"LONsurf and G-CSF Use: Being On A Right Dose-intensity to Optimize Treatment Efficacy","status":"ACTIVE_NOT_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2020-05-20","conditions":"Metastatic Colorectal Cancer","enrollment":176},{"nctId":"NCT05328908","phase":"PHASE3","title":"A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2022-04-28","conditions":"Colorectal Neoplasms","enrollment":770},{"nctId":"NCT07116577","phase":"PHASE2","title":"Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC","status":"NOT_YET_RECRUITING","sponsor":"Jinan Central Hospital","startDate":"2025-08-31","conditions":"mCRC","enrollment":37},{"nctId":"NCT07090031","phase":"PHASE2","title":"Perioperative Treatment With TAS-102 in Combination With Oxaliplatin for Locally Advanced Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Qingdao Central Hospital","startDate":"2025-07-01","conditions":"EFS, pCR Rate","enrollment":49},{"nctId":"NCT07085169","phase":"PHASE2","title":"Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-08-01","conditions":"Colo-rectal Cancer, Third-line and Beyond Therapy, TAS 102","enrollment":50},{"nctId":"NCT04923529","phase":"PHASE2","title":"TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2021-03-01","conditions":"Pancreas Cancer","enrollment":28},{"nctId":"NCT06199973","phase":"PHASE3","title":"Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2024-03-01","conditions":"Advanced Colorectal Cancer","enrollment":130},{"nctId":"NCT04879368","phase":"PHASE3","title":"RegoNivo vs Standard of Care Chemotherapy in AGOC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2021-06-01","conditions":"Gastro-Oesophageal Cancer","enrollment":450},{"nctId":"NCT07071844","phase":"PHASE2","title":"BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients","status":"NOT_YET_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2025-09","conditions":"Metastatic Colorectal Cancer","enrollment":162},{"nctId":"NCT06873763","phase":"PHASE1, PHASE2","title":"Nelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal Cancer","status":"RECRUITING","sponsor":"STCube, Inc.","startDate":"2025-06-09","conditions":"Metastatic Colorectal Cancer (CRC), Recurrent Colorectal Cancer","enrollment":52},{"nctId":"NCT05508737","phase":"PHASE1, PHASE2","title":"Pembrolizumab and Trifluridine/Tipiracil With Previously Treated Advanced Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yonsei University","startDate":"2022-12-01","conditions":"Gastric and Gastroesophageal Junction Adenocarcinoma","enrollment":75},{"nctId":"NCT06850090","phase":"PHASE3","title":"Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial","status":"NOT_YET_RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2025-07-30","conditions":"Rectal Cancer, Rectal Cancer Patients","enrollment":210},{"nctId":"NCT07012954","phase":"PHASE1, PHASE2","title":"ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-06-01","conditions":"Colorectal Cancer Metastatic","enrollment":64},{"nctId":"NCT05854498","phase":"PHASE2","title":"Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2023-10-13","conditions":"Metastatic Colorectal Cancer","enrollment":25},{"nctId":"NCT05201352","phase":"PHASE1, PHASE2","title":"Evaluation of Efficacy of Trifluridine/Tipiracil Plus an Anti-IL-1α True Human Antibody Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Georges Francois Leclerc","startDate":"2022-10-13","conditions":"Metastatic Colorectal Cancer","enrollment":160},{"nctId":"NCT04393298","phase":"PHASE1, PHASE2","title":"A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2020-07-09","conditions":"Advanced Solid Tumors","enrollment":93},{"nctId":"NCT06992648","phase":"PHASE3","title":"Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-04-01","conditions":"Colorectal Cancer Metastatic, Colorectal Cancer Recurrent","enrollment":302},{"nctId":"NCT05481463","phase":"PHASE2","title":"Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2023-01-30","conditions":"Pancreatic Neoplasms","enrollment":22},{"nctId":"NCT05312398","phase":"PHASE2","title":"CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2021-07-15","conditions":"Metastatic Colorectal Adenocarcinoma","enrollment":219},{"nctId":"NCT05848739","phase":"PHASE1","title":"A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Sapience Therapeutics","startDate":"2023-06-05","conditions":"Colon Cancer, Metastatic Colon Cancer","enrollment":130},{"nctId":"NCT04097028","phase":"PHASE2","title":"Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2019-12-20","conditions":"Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8","enrollment":22},{"nctId":"NCT05965531","phase":"PHASE2","title":"Treating Locally Advanced Rectal Cancer With TAS-102 Chemotherapy Plus Neoadjuvant Radiotherapy","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-01-01","conditions":"Rectal Cancer","enrollment":65},{"nctId":"NCT04868773","phase":"PHASE1","title":"Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Irvine","startDate":"2021-07-16","conditions":"Colorectal Cancer, Colorectal Carcinoma, Metastatic Cancer","enrollment":12},{"nctId":"NCT04920032","phase":"PHASE1","title":"Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2021-08-26","conditions":"Colon Adenocarcinoma, Colorectal Cancer","enrollment":22},{"nctId":"NCT04450836","phase":"PHASE2","title":"Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"UNICANCER","startDate":"2020-11-23","conditions":"Metastatic Colorectal Cancer","enrollment":234},{"nctId":"NCT06882915","phase":"PHASE1","title":"Efficacy and Safety of Trifluridine/tipiracil (TAS-102) Combined with Bevacizumab and Putalimab in the Treatment of Patients with MCRC After Cytoreductive Surgery: a Single-arm, Single-center Clinical Study","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-05-01","conditions":"Colorectal Cancer (CRC)","enrollment":20},{"nctId":"NCT06872606","phase":"PHASE2","title":"Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for Total Neoadjuvant Therapy of Microsatellite Stable (MSS) Locally Advanced Low Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sir Run Run Shaw Hospital","startDate":"2025-04-01","conditions":"Rectal Adenocarcinoma","enrollment":33},{"nctId":"NCT06522919","phase":"PHASE2","title":"Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2025-01-07","conditions":"Colorectal Cancer Metastatic, Microsatellite Stable Colorectal Carcinoma, Refractory Mismatch-repair-proficient (pMMR) Metastatic Colorectal Cancer","enrollment":36},{"nctId":"NCT03368963","phase":"PHASE1, PHASE2","title":"TAS102 in Combination With NAL-IRI in Advanced GI Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2018-01-30","conditions":"Colorectal Adenocarcinoma, Gastric Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma","enrollment":64},{"nctId":"NCT04260269","phase":"","title":"Feasibility of Switching Fluoropyrimidine Due to Cardiotoxicity Study","status":"ENROLLING_BY_INVITATION","sponsor":"Helsinki University Central Hospital","startDate":"2018-06-01","conditions":"Solid Tumor","enrollment":200},{"nctId":"NCT03665506","phase":"","title":"Trifluridin/tipirACil in MeTastatIc Colorectal Cancer","status":"COMPLETED","sponsor":"Servier","startDate":"2018-06-25","conditions":"Metastatic Colorectal Cancer","enrollment":315},{"nctId":"NCT06711471","phase":"PHASE2","title":"Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer","status":"RECRUITING","sponsor":"LIN YANG","startDate":"2024-11-14","conditions":"Gastric Cancer Adenocarcinoma Metastatic","enrollment":31},{"nctId":"NCT04701476","phase":"PHASE2","title":"TATE and Pembrolizumab (MK3475) in mCRC and NSCLC","status":"RECRUITING","sponsor":"Teclison Ltd.","startDate":"2021-05-20","conditions":"Colorectal Cancer; Lung Cancer","enrollment":110},{"nctId":"NCT04294264","phase":"PHASE2","title":"TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2019-02-12","conditions":"Metastatic Colorectal Carcinoma, Recurrent Colon Carcinoma, Refractory Colorectal Carcinoma","enrollment":50},{"nctId":"NCT02261532","phase":"PHASE1","title":"A Phase I Study of TAS-102 in Solid Tumors","status":"COMPLETED","sponsor":"Taiho Pharmaceutical Co., Ltd.","startDate":"2014-09","conditions":"Advanced or Metastatic Solid Tumors","enrollment":15},{"nctId":"NCT05476796","phase":"PHASE2","title":"Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2023-06-23","conditions":"Gastric Adenocarcinoma, Esophagus Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":118},{"nctId":"NCT03251378","phase":"PHASE1","title":"A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers","status":"COMPLETED","sponsor":"Hutchison Medipharma Limited","startDate":"2017-12-11","conditions":"Advanced Solid Tumors, Metastatic Colon Cancer, Metastatic Breast Cancer","enrollment":129},{"nctId":"NCT04999761","phase":"PHASE1","title":"AB122 Platform Study","status":"RECRUITING","sponsor":"Taiho Pharmaceutical Co., Ltd.","startDate":"2021-06-01","conditions":"Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer","enrollment":917},{"nctId":"NCT04737187","phase":"PHASE3","title":"Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients","status":"COMPLETED","sponsor":"Taiho Oncology, Inc.","startDate":"2020-11-25","conditions":"Refractory Metastatic Colorectal Cancer","enrollment":492}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lonsurf"],"phase":"marketed","status":"active","brandName":"Trifluridine and Tipiracil","genericName":"Trifluridine and Tipiracil","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Trifluridine is a nucleoside analog that inhibits thymidylate synthase and gets incorporated into DNA to damage cancer cells, while tipiracil is a thymidine phosphorylase inhibitor that enhances trifluridine bioavailability. Used for Metastatic colorectal cancer (previously treated), Metastatic gastric cancer (previously treated).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}